1. Pink Sheet

Regulators Want Reduced Animal Testing – Could AI Be The Answer?

 
• By Eliza Slawther

AI modeling can predict which animal tests are useful and necessary, saving money for companies and meeting objectives set by regulators in the US and EU, VeriSIM Life’s CEO and founder Jo Varshney tells the Pink Sheet.

Animal testing ban
• Source: Shutterstock

Drug regulators are increasingly pushing for reduced animal testing, particularly in the EU, where it was recently announced that the use of the traditional rabbit pyrogen test (RPT) will be abolished next year as a requirement for controlling drug product pyrogenicity.

Jo Varshney, founder and CEO of VeriSIM Life, a US company that uses AI to help pharmaceutical companies improve drug discovery and development, told the Pink Sheet that she foresees...

Key Takeaways

  • Regulators such as the US FDA and the EMA are beginning to accept alternatives to animal testing in pharmaceutical R&D.

  • VeriSIM Life’s CEO says...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Interviews

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an audio interview.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.

Kiji CEO On EU HTA Regulation, Hospital Exemption And The Future Of ATMPs

 
• By Eliza Slawther

Miguel Forte, CEO of Kiji Therapeutics, tells the Pink Sheet why he is confident in the future of gene therapies, despite the global “turmoil” that is impacting investment in the industry and changes to the EU and US regulatory landscapes.